Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Pfizer and BioNTech win EUA for booster for individuals 16 and older

By Brian Buntz | December 9, 2021

Pfizer-BioNTechPfizer Inc. (NYSE:PFE) and its partner BioNTech SE (NSDQ:BNTX) have received emergency use authorization for BNT162b2 mRNA COVID-19 vaccine for individuals at least 16 years old.

To coincide with the announcement, CDC Director Dr. Rochelle Walensky recommended that everyone 16 and older receive a booster. “Although we don’t have all the answers on the Omicron variant, initial data suggests that COVID-19 boosters help broaden and strengthen the protection against Omicron and other variants,” Walensky said. Recipients need to wait at least six months after completing the primary vaccination series.

The Pfizer-BioNTech is now the only COVID-19 vaccine to win authorization for adolescents between 16 and 17.

“Today’s decision by the FDA to further expand the Emergency Use Authorization of a booster dose of our COVID-19 vaccine is a critical milestone as we continue to stay vigilant in addressing the virus,” said Albert Bourla, Pfizer CEO, in a press release.

In related news, Pfizer also said that the Omicron variant could spur interest in a fourth COVID-19 vaccine booster earlier than anticipated — perhaps six months after dose three, Bourla said in a Bloomberg interview.

Pfizer-BioNTech vaccine

Pfizer-BioNTech vaccine image courtesy of Wikimedia Commons.

Pfizer and its partner BioNTech are developing a variant-specific booster but are uncertain whether it is necessary. The companies anticipate that such a booster would be ready in March, according to a Bloomberg interview with Bourla. An Omicron-specific variant could be less protective against the Delta variant, but having boosters available for both Delta and Omicron variants would give health authorities greater flexibility in fighting the pandemic.

Bourla anticipates that more data will be available in the coming weeks concerning the performance of the BNT162b2 vaccine against the Omicron variant.


Filed Under: clinical trials, Drug Discovery
Tagged With: BioNTech SE, coronavirus, covid-19, FDA, Pfizer, vaccine
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50